A Phase 2 interventional study of Acetaminophen ER and Placebo in Dental Pain, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.. Completed at 1 site in United States. Open to participants aged 17 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-07-10.
Sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.
Among the 54 studies in Toothache with a site in United States, this one is the 7th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2013, is one of 20 in phase 2, and was the 29th registered.
142 studies on the registry are indexed under Toothache; 28 are open to participants now.
Browse Toothache studies →6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:
Cytogel Pharma, LLC · Sites in United States
Ages 18–45 · Healthy volunteers
University of Florida · Sites in United States
Ages 18+ · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 6–12 · Healthy volunteers
Cleveland Dental Institute · Sites in United States
Ages 20–60
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 17 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 11 · Phase 4 10
First in 2004; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 403 is above the median of 84 across 123 interventional studies indexed under Toothache.
Median enrollment 194 across the 50 interventional studies, 82 across the 4 observational. Of the 45 that completed or were terminated, 30 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Johnson & Johnson has 6 studies filed under Toothache — fewer than ten, so there is no comparison to draw.
4 of the studies in Toothache with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT06330207University of FloridaAn Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) | 2027-02-01 |
| NCT06691269University of Maryland, BaltimorePhotobiomodulation and Tooth Analgesia | 2027-06 |
| NCT07905105Cytogel Pharma, LLCA Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Toothache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of acetaminophen ER 1500 mg (two 750 mg tablets) over 10 to 12 hours in the dental pain model following third molar extraction(s) and to evaluate the pharmacokinetics of acetaminophen ER 1500 mg (two 750 mg tablets) in a sub-group of subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Acetaminophen ER
Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
Drug: Placebo
Single dose (2 tablets) Acetaminophen ER 750 mg
Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
Time Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10)
Time weighted sum of pain intensity difference scores from baseline over 10 hours. Pain intensity was evaluated using a 0-10 numerical rating scale (NRS) where 0 = no pain and 10 = very severe pain. SPID 0-10 = 0.25 x (PID at 15 min + PID at 30 min + PID at 45 min + PID at 60 min + PID at 75 min + PID at 90 min) + 0.5 x (PID at 120 min) + PID at 3 h + PID at 4 h + PID at 5 h + PID at 6 h + PID at 7 h + PID at 8 h + PID at 9 h + PID at 10 h.
Time frame: 10 Hours
Time to Confirmed First Perceptible Pain Relief
Minutes until confirmed first perceptible pain relief was achieved. Stopwatch was started after the subject took the study medication. The subject was instructed to stop the stopwatch when they first began to feel any pain relief. The first perceptible pain relief was confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.
Time frame: Within 12 Hours
Time to Meaningful Pain Relief
Minutes until meaningful pain relief was achieved. Stopwatch was started after the subject took the study medication. The subjects were instructed to stop the stopwatch when the relief from the starting pain was meaningful to them.
Time frame: Within 12 Hours
Duration of Pain Relief
Minutes until rescue medication was given.
Time frame: Within 12 Hours
Patient Global Evaluation
Patient Assessment of the pain medication - Number of subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent.
Time frame: 12 Hours
| Milestone | Placebo | ACE ER 1500 mg |
|---|---|---|
| Started | 134 | 269 |
| Completed | 133 | 268 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Could not swallow study medication | 0 | 1 |
Time weighted sum of pain intensity difference scores from baseline over 10 hours. Pain intensity was evaluated using a 0-10 numerical rating scale (NRS) where 0 = no pain and 10 = very severe pain. SPID 0-10 = 0.25 x (PID at 15 min + PID at 30 min + PID at 45 min + PID at 60 min + PID at 75 min + PID at 90 min) + 0.5 x (PID at 120 min) + PID at 3 h + PID at 4 h + PID at 5 h + PID at 6 h + PID at 7 h + PID at 8 h + PID at 9 h + PID at 10 h.
| units on a scale | Placebo | ACE ER 1500 mg |
|---|---|---|
| Time Weighted Sum of Pain Intensity Difference (PID) Over 10 Hours (SPID 0-10) | 5.745 ± 2.5056 | 30.986 ± 1.8951 |
Minutes until confirmed first perceptible pain relief was achieved. Stopwatch was started after the subject took the study medication. The subject was instructed to stop the stopwatch when they first began to feel any pain relief. The first perceptible pain relief was confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.
| Minutes | Placebo | ACE ER 1500 mg |
|---|---|---|
| Time to Confirmed First Perceptible Pain Relief | NA (NA to NA) | 26.817 (23.683 to 29.950) |
Minutes until meaningful pain relief was achieved. Stopwatch was started after the subject took the study medication. The subjects were instructed to stop the stopwatch when the relief from the starting pain was meaningful to them.
| Minutes | Placebo | ACE ER 1500 mg |
|---|---|---|
| Time to Meaningful Pain Relief | NA (NA to NA) | 84.675 (66.333 to 120.633) |
Minutes until rescue medication was given.
| Minutes | Placebo | ACE ER 1500 mg |
|---|---|---|
| Duration of Pain Relief | 106.5 (99.000 to 132.000) | NA (NA to NA) |
Patient Assessment of the pain medication - Number of subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent.
| percentage of participants | Placebo | ACE ER 1500 mg |
|---|---|---|
| Poor (0) | 63.2 | 18.3 |
| Fair (1) | 9.0 | 11.2 |
| Good (2) | 8.3 | 14.6 |
| Very Good (3) | 12.8 | 35.8 |
| Excellent (4) | 6.8 | 20.1 |
Collected over Day 5-7 for non-serious adverse events, until 30 days after the last study site visit for serious adverse events.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/134 (0%) | 14/134 (10.4%) |
| ACE ER 1500 mg | — | 0/268 (0%) | 26/268 (9.7%) |
| Event | Placebo | ACE ER 1500 mg |
|---|---|---|
| NauseaGastrointestinal disorders | 14/134 | 26/268 |
| Age, Continuous(years) | Placebo | ACE ER 1500 mg | Total |
|---|---|---|---|
| Mean | 19.6 ± 2.66 | 19.5 ± 2.82 | 19.6 ± 2.77 |
| Sex: Female, Male(Participants) | Placebo | ACE ER 1500 mg | Total |
|---|---|---|---|
| Female | 72 | 143 | 215 |
| Male | 62 | 126 | 188 |
| Region of Enrollment(participants) | Placebo | ACE ER 1500 mg | Total |
|---|---|---|---|
| USA | 134 | 269 | 403 |
The record gives a start of Oct 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 1 year 2 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. →